Journal article
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
American journal of hematology, Vol.91(11), pp.1096-1101
11/2016
DOI: 10.1002/ajh.24492
PMCID: PMC5073042
PMID: 27465588
Abstract
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1-3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002-2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re-treatment, or death due to any cause. OS was compared to age-and-sex-matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR = 3.72, 95%CI: 2.78-4.88; Lyon SMR = 8.74, 95%CI: 5.41-13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR = 0.73, 95%CI: 0.56-0.94, Lyon SMR = 1.02, 95%CI: 0.58-1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR = 17.63, 95%CI:11.97-25.02, Lyon SMR = 19.10, 95%CI:9.86-33.36; EFS24 failure: MER SMR = 13.02, 95%CI:9.31-17.74, Lyon SMR = 7.22, 95%CI:4.13-11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL. Am. J. Hematol. 91:1096-1101, 2016. © 2016 Wiley Periodicals, Inc.
Details
- Title: Subtitle
- Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
- Creators
- Matthew J Maurer - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. maurer@mayo.EduEmmanuel Bachy - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceHervé Ghesquières - Department of Medical Oncology, Centre Léon Bérard, Lyon, FranceStephen M Ansell - Division of Hematology, Mayo Clinic, Rochester, MinnesotaGrzegorz S Nowakowski - Division of Hematology, Mayo Clinic, Rochester, MinnesotaCarrie A Thompson - Division of Hematology, Mayo Clinic, Rochester, MinnesotaDavid J Inwards - Division of Hematology, Mayo Clinic, Rochester, MinnesotaCristine Allmer - Department of Health Sciences Research, Mayo Clinic, Rochester, MinnesotaCatherine Chassagne-Clément - Department of Pathology, Centre Léon Bérard, Lyon, FranceEmmanuelle Nicolas-Virelizier - Department of Medical Oncology, Centre Léon Bérard, Lyon, FranceCatherine Sebban - Department of Medical Oncology, Centre Léon Bérard, Lyon, FranceLaure Lebras - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceClementine Sarkozy - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceWilliam R Macon - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MinnesotaAndrew L Feldman - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MinnesotaSergei I Syrbu - Department of Pathology, University of Iowa, Iowa City, IAAlexandra Traverse-Glehan - Department of Pathology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceBertrand Coiffier - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceSusan L Slager - Department of Health Sciences Research, Mayo Clinic, Rochester, MinnesotaGeorge J Weiner - Department of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, IAThomas E Witzig - Division of Hematology, Mayo Clinic, Rochester, MinnesotaThomas M Habermann - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceGilles Salles - Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, FranceJames R Cerhan - Department of Health Sciences Research, Mayo Clinic, Rochester, MinnesotaBrian K Link - Department of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.91(11), pp.1096-1101
- Publisher
- United States
- DOI
- 10.1002/ajh.24492
- PMID
- 27465588
- PMCID
- PMC5073042
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Grant note
- P30 CA015083 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 11/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984047778302771
Metrics
17 Record Views